|Bid||27.01 x 0|
|Ask||27.09 x 0|
|Day's Range||27.00 - 28.50|
|52 Week Range||7.32 - 46.00|
|PE Ratio (TTM)||188.81|
|Earnings Date||Jun 11, 2018 - Jun 15, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.00|
CanniMed Shares Delisted from TSX TSX: ACB TSX: CMED EDMONTON , May 1, 2018 /CNW/ - Aurora Cannabis Inc. (" Aurora " or the " Company ") (TSX:ACB) (OTCQB:ACBFF) (Frankfurt : 21P; WKN:A1C4WM) ...
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
WKN: A1C4WM), CanniMed Therapeutics Inc. ("CanniMed") (TSX:CMED.TO - News) and CTT Pharmaceutical Holdings, Inc., ("CTT") (OTC:CTTH - News) announced today that further to the CanniMed/CTT news release of February 17, 2017, the companies have entered into a three-way agreement that provides Aurora, through its ownership of CanniMed, with joint exclusivity on the distribution in Canada of CTT's novel, patented drug delivery technologies. This collaboration includes the licensing by CTT to CanniMed and Aurora of six patents related to cannabinoid delivery for pain management that will enable CanniMed and Aurora to exclusively develop and commercialize this unique, sub-lingual (beneath the tongue) wafer, drug delivery system in Canada.
TSX: ACB TSX: CMED EDMONTON , April 13, 2018 /CNW/ - Aurora Cannabis Inc. (" Aurora ") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt : 21P; WKN: A1C4WM) announced today that the Company has exercised ...
Canopy Growth Corp. (TSX:WEED), Aurora Cannabis Inc. (TSX:ACB) and Aphria Inc. (TSX:APH) have all struggled as of late, but there is no need to panic.
WKN: A1C4WM) and CanniMed Therapeutics Inc. ("CanniMed") (TSX:CMED.TO - News) announced today that CanniMed has entered into a Letter of Intent to become a preferred supplier of medical cannabis to Pharmasave. A member governed cooperative of more than 650 independently owned community pharmacies across the country, Pharmasave is one of Canada's leading independent community pharmacies.
Aurora Cannabis senior vice president Andrċ Jérôme, previously tasked with heading the acquisition of CanniMed, will serve as interim CEO. Aurora is almost set to close the purchase of CanniMed, creating the world's most valuable weed firm after months of tensions between the companies.
WKN: A1C4WM) and CanniMed Therapeutics Inc. ("CanniMed") (TSX:CMED.TO - News) announced today that Mr. Brent Zettl has resigned from his position as CEO of CanniMed, effective immediately, to pursue other opportunities. Mr. Zettl has agreed to remain available to CanniMed and Aurora in an advisory capacity to assist during the integration period. "CanniMed is the pioneer in the Canadian medical cannabis industry and this is in no small part thanks to Brent and the huge contributions he has made to the development of the sector.
WKN: A1C4WM) announced today that with the second take-up under its offer to acquire all of the outstanding shares of CanniMed Therapeutics Inc. ("CanniMed") (TSX:CMED.TO - News), the Company now owns approximately 95.9% of CanniMed common shares (the "CanniMed Shares"). The Company intends to acquire the remaining outstanding shares it does not already own through a compulsory share acquisition, pursuant to the Canada Business Corporations Act. The transaction unites Aurora, one of the world's largest and fastest growing cannabis companies, with CanniMed, a pioneering cannabis company that has been operating in the industry longer than any other competitor, and whose brand strongly resonates with the medical community.
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
HORIZNS MARIJUNA LF CL A UNT ETF (TSX:HMMJ) is up an impressive 95% since the start of November. But several cannabis stocks have fared even better. Find out which ones.
Aurora Cannabis Inc. (TSX:ACB) is setting the stage for massive post-legalization growth, but is the potential reward worth the risk?
CanniMed Therapeutics Inc. today released its unaudited financial results of operations for the three months ended January 31, 2018. The information in this news release should be read in conjunction with the Company’s condensed consolidated interim financial statements and notes thereto for the three months ended January 31, 2018 and the Company’s audited consolidated financial statements and notes ...
Aurora Cannabis Inc. (TSX:ACB) made several big moves lasts month to secure distribution and bolster its product line. Will it help the company come July 1, when recreational cannabis becomes legal?
CanniMed Therapeutics Inc. announces that it plans to release its financial results for the three months ended January 31, 2018 before markets open on Monday, March 19, 2018.
Aurora Cannabis Inc. and CanniMed Therapeutics Inc. announced today that following the successful take up and payment of approximately 86.8% of the issued and outstanding of CanniMed Shares, three Aurora Cannabis appointees will join the CanniMed Board of Directors, effective immediately.
TSX: ACB TSX: CMED EDMONTON and SASKATOON , March 15, 2018 /CNW/ - Aurora Cannabis Inc. (" Aurora ") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt : 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. (" ...
Could the high uptake of cash offer to CanniMed Therapeutics Inc. (TSX:CMED) investors imply a depressed near-term view on Aurora Cannabis Inc.'s (TSX:ACB) valuation?
On Friday, Aurora Cannabis Inc. (TSX:ACB) announced it has agreed to terms with CanniMed Therapeutics Inc. (TSX:CMED) and will begin integrating the firm. Here's what it means for shareholders in terms of dilution.